Quick Answer
BioCardia, Inc. reported Total Revenue of $479.0 thousand for fiscal year 2017.
BioCardia, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | — | — | — | — | — | — |
| Net Income | -$8.23M -3.5% |
-$7.95M +31.3% |
-$11.57M +2.8% |
-$11.91M +5.7% |
-$12.62M +15.9% |
-$15.00M -2.0% |
| Total Assets | $3.41M -8.4% |
$3.72M +24.7% |
$2.99M -69.5% |
$9.79M -37.7% |
$15.72M -32.9% |
$23.42M +205.1% |
| Cash and Equivalents | $2.50M +5.3% |
$2.37M +115.0% |
$1.10M -85.0% |
$7.36M -42.8% |
$12.87M -39.9% |
$21.41M +283.3% |
| Stockholders Equity | $895.0K +6.9% |
$837.0K +152.2% |
-$1.60M -132.8% |
$4.89M -52.8% |
$10.38M -45.9% |
$19.18M +709.1% |
| R&D Expense | $4.96M +13.1% |
$4.39M -43.2% |
$7.73M -12.5% |
$8.83M +3.2% |
$8.56M -12.8% |
$9.81M +14.6% |
| Operating Income | -$8.28M -3.5% |
-$8.00M +31.3% |
-$11.64M +2.2% |
-$11.90M +5.8% |
-$12.63M +18.7% |
-$15.53M -9.3% |
| Gross Profit | — | — | — | — | — | — |
| Shares Outstanding | 10.76M +133.8% |
4.60M -80.6% |
23.67M +17.9% |
20.08M +19.0% |
16.87M +3.5% |
16.30M +138.8% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2017 | $130.0K | +11.1% | +16.1% |
| Net Income | September 30, 2025 | -$1.48M | +14.6% | +27.6% |
| Total Assets | September 30, 2025 | $6.15M | -1.9% | +194.3% |
| Cash and Equivalents | September 30, 2025 | $5.29M | +7.2% | +439.5% |
| Stockholders Equity | September 30, 2025 | $2.63M | -4.6% | +239.3% |
| R&D Expense | September 30, 2025 | $936.0K | +0.5% | -31.6% |
| Operating Income | September 30, 2025 | -$1.49M | +15.3% | +27.5% |
| Gross Profit | June 30, 2013 | $69.0K | +305.9% | +81.6% |
| Shares Outstanding | September 30, 2025 | 10.61M | +134.5% | +92.7% |
- BioCardia, Inc. reported Total Revenue of $479.0 thousand for fiscal year 2017.
- BioCardia, Inc. showed a decrease of -16.8% in Total Revenue compared to the prior fiscal year.
- BioCardia, Inc. reported Net Income of -$8.23 million for fiscal year 2025.
- BioCardia, Inc. showed a decrease of -3.5% in Net Income compared to the prior fiscal year.
- BioCardia, Inc. reported Total Assets of $3.41 million for fiscal year 2025.
- BioCardia, Inc. showed a decrease of -8.4% in Total Assets compared to the prior fiscal year.
- BioCardia, Inc. reported Cash and Equivalents of $2.50 million for fiscal year 2025.
- BioCardia, Inc. showed an increase of +5.3% in Cash and Equivalents compared to the prior fiscal year.
- BioCardia, Inc. reported Stockholders Equity of $895.0 thousand for fiscal year 2025.
- BioCardia, Inc. showed an increase of +6.9% in Stockholders Equity compared to the prior fiscal year.
- BioCardia, Inc. reported R&D Expense of $4.96 million for fiscal year 2025.
- BioCardia, Inc. showed an increase of +13.1% in R&D Expense compared to the prior fiscal year.
- BioCardia, Inc. reported Operating Income of -$8.28 million for fiscal year 2025.
- BioCardia, Inc. showed a decrease of -3.5% in Operating Income compared to the prior fiscal year.
- BioCardia, Inc. reported Gross Profit of $62.0 thousand for fiscal year 2012.
- BioCardia, Inc. showed an increase of +416.7% in Gross Profit compared to the prior fiscal year.
- BioCardia, Inc. reported Shares Outstanding of 10.76 million shares for fiscal year 2025.
- BioCardia, Inc. showed an increase of +133.8% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: